Mistrials declared in Los Angeles Vioxx cases

Share this article:
A Los Angeles judge declared mistrials in the cases of two men who blame Merck’s withdrawn painkiller Vioxx for their heart attacks. Rudolph Arrigale and Lawrence Appell, plaintiffs in the two cases tried together, claimed that Merck failed to disclose known dangers of the medicine. Attorneys for Merck argued that both men were at risk for heart injuries regardless of whether they were taking Vioxx. Jurors were deadlocked in the trial presided over by Judge Victoria Chaney. Seven answered “yes” that Appell’s doctor should have recognized the risks of Vioxx, while five answered “no.” A nine-member majority was needed to move beyond that question on the jury questionnaire. Appell’s attorney, Brian Panish, said in a Reuters report that a new trial could begin as early as April. Merck spokesman Thomas Yoo, said there had been no discussions about a potential settlement. “If either of these plaintiffs want to go again, we’ll be ready.” Yoo said. The jury deliberated for about six days, which was broken up by a three-week break for the holidays, Reuters reported. One juror was replaced after she informed the judge that a relative had taken Vioxx. Meanwhile, the widow of man who blamed Vioxx for the heart attack and death of her husband dropped her lawsuit five weeks before the trial was set to start. The suit was voluntarily dismissed “with prejudice,” meaning it cannot be filed again, Merck said in a statement. As of Sept. 30, claims related to more than 3,000 alleged Vioxx users have been dismissed before being scheduled for trial, including more than 1,100 dismissed with prejudice, Merck said.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...